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FORMULASI LIPOSOM SEBAGAI PEMBAWA DRUG UNTUK 
BUPARVAQUONE 
 
ABSTRAK 
Kajian ini merangkumi penyediaan liposom sebagai pembawa drug buparvaquone 
yang merupakan ubat bagi rawatan penyakit leishmaniasis. Kajian awal bertumpu 
untuk menggantikan penggunaan klorofom dengan etanol sebagai pelarut lipid. 
Keputusan yang diperoleh menunjukkan liposom boleh dilarutkan dalam etanol dan 
klorofom boleh dikecualikan dari formulasi.  Liposom tanpa drug disediakan melalui 
dua kaedah berbeza iaitu kaedah tradisional Bangham dan juga kaedah suntikan 
etanol. Kajian awal juga dijalankan bagi mengenalpasti factor-faktor yang 
mempengaruhi saiz dan polidispersiti liposom yang dihasilkan. Liposom juga diuji 
dengan menambah kolesterol dan alpha-tocopherol sebagai penstabil partikel 
liposom. Kajian menunjukkan liposom kaedah suntikan etanol lebih stabil 
berbanding liposom kaedah tradisional Bangham. Liposom yang dihasilkan 
menggunakan kaedah tradisional Bangham dikecualikan bagi ujian pelepasan dan 
pemerangkapan BPQ disebabkan ujian fizikokimia menunjukkan ia tidak stabil 
dalam jangka masa panjang. Berbeza dengan liposom kaedah suntikan etanol di 
mana hasil kajian menunjukkan kestabil untuk 6 bulan dengan ukuran saiz dan 
polidispersiti masih kurang dari 0.200. Liposom tanpa drug menunjukkan saiz dan 
polidispersiti lebih kecil berbanding dengan liposom yang telah dimasukkan drug 
BPQ. Liposom bagi pemerangkapan Bupavarquone menggunakan dua formulasi. 
Formulasi pertama adalah lecithin 100 mg dengan kolesterol 50 mg. Formulasi kedua 
yang digunakan mengandungi 100mg lecithin dan 50mg alpha-tocopherol. Liposom 
dicirikan mengikuti beberapa ujian pencirian fizikokimia termasuk ujian 
xx 
 
pemerangkapan dan ujian pelepasan buparvaquone (BPQ) secara in vitro selama 24 
jam.Liposom mengandungi BPQ menunjukkan kejayaan  inkorporasi ubat sebanyak 
60-85%. Bagaimanapun penambahan kadar ubat yang terlalu tinggi iaitu 40 mg 
Buparvaquone mengakibatkan penurunan peratusan pemerangkapan BPQ dalam 
liposom. Bagi kajian pelepasan ubatan lebih daripada 80% ubatan telah berjaya 
dilepaskan dari liposom dalam masa 24 jam. Keputusan dan penemuan yang 
diperoleh menunjukkkan liposom mempunyai potensi yang amat sesuai untuk 
digunakan bagi rawatan leishmaniasis yang bertumpu di system RES. 
Kesimpulannya dua formulasi liposom yang mampu berfungsi sebagai pembawa 
drug buparvaquone telah telah berjaya dihasilkan menggunakan kaedah suntikan 
etanol dan boleh digunakan di masa hadapan bagi kajian kajian in vivo untuk 
mengkaji potensinya mengubati penyakit leishmaniasis. 
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FORMULATION OF LIPOSOMES AS A DRUG CARRIER FOR 
BUPARVAQUONE  
 
ABSTRACT 
 
This study was carried out to encapsulate the drug buparvaquone (BPQ) and to study 
its physiochemical properties and along with its in vitro release study. Initial studies 
focused on elimination of chloroform as lipid solvent and its substitution with 
ethanol. Result obtained showed that chloroform can be substituted with ethanol. 
Two different fabrication methods were used to produce liposomes: 1) the classic 
Bangham method and 2) ethanol injection method. Preliminary study was conducted 
to study the parameters that affect the particle size and polydispersity index (PDI). 
Liposomes were formulated with the addition of stabilizers, cholesterol and alpha-
tocopherol. The liposomes were characterized based on physicochemical 
characteristics to record their effects on size and polydispersity. Two formulations 
obtained from the ethanol injection method were used for loading of buparvaquone 
whereby the first formulation with 100mg lecithin and 50mg cholesterol, the second 
one with 100mg lecithin and 50mg alpha-tocopherol. The study conducted for BPQ 
loading and BPQ encapsulation eliminated Bangham method liposomes as the 
stability study showed that the particle size and polydispersity increased to above 
0.200 within 6 months whilst ethanol injection particles remained stable over same 
period of time. The BPQ loaded particles for ethanol injection method were larger in 
size but did not exceed 200nm. The encapsulation efficiency of liposome formulated 
with cholesterol and alpha tocopherol showed similar encapsulation percentage. The 
increase in drug: lipid ratio resulted in lower encapsulation efficiency. The drug 
xxii 
 
release study showed more than 80% of drug was released by 24 hours of study. The 
findings of this study suggest that production of liposome particles successfully 
encapsulated the drug buparvaquone. Two formulations were successfully 
formulated. These formulations can be used for further in vivo studies on Leishmania 
cells. It has a huge potential to be used for further development in the treatment of 
leishmaniasis.  
1 
 
CHAPTER ONE 
INTRODUCTION 
1.1PROBLEM STATEMENT  
The high prevalence of leishmaniasis in countries like Africa, India, Bangladesh and 
many other countries and the emergence of resistance to conventional drugs 
demonstrate the need to develop less toxic and more efficient treatments. There is a 
limited safe therapeutic option to treat visceral leishmaniasis. Quite often, the drug 
treatments result in poor patience compliance and relapses occur due to the 
unfinished treatments and the severe adverse effects (den Boer et al., 
2009 and Murray, 2001).  
 Currently, there are two formulations in use: sodium stibogluconate (SSG) 
and meglumine antimoniate. Both formulations have comparable efficacy and 
toxicity. They have poor oral absorption and are given via intramuscular or 
intravenous injections. Common side effects include nausea and vomiting, hepatitis 
and pancreatitis. Gastrointestinal symptoms appear a major risk factor for death 
during treatment with SSG. 
Miltefosine is a membrane active alkyl phospholipid, originally used as an 
anticancer drug. It was found to have antileishmania activity in animal models in the 
early 1990s. It is active orally. Animal studies have shown that it has some 
reproductive toxicity and thus it is contraindicated in pregnancy, and needs to be 
used with caution in women of reproductive age. However, the long half life (seven 
days) makes the risk of developing parasites resistant to miltefosine a real possibility. 
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The use of LAB was initially limited in the early 1990s in resource rich 
countries to a second line drug when VL parasites persisted despite SSG treatment. 
The evaluation of efficacies of different Amphotericin B formulations (Fungizone, 
Ambisome, Abelcet, and Amphocil) in a murine model of visceral leishmaniasis 
showed that liposomal Amphotericin B formulation could successfully cured the 
infection with a 21-day course (50 mg/day) of (Khan and Owais, 2006) in the cases 
where leishmaniasis was unresponsive to several courses of treatment with the 
standard drugs (antimonials). In India some 90% of patients with visceral 
leishmaniasis were successfully treated with liposomal Amphotericin B in treatment 
regimens as brief as 5 days. The liposomal Amphotericin B thus offered a remedy for 
the principal drawback of all other antileishmanial agents which have a prolonged 
duration of treatment. Currently, AmBisome is the only liposomal product approved 
for the treatment of visceral leishmaniasis in adult and pediatrics and considered the 
first choice for patients who are unresponsive to antimonials (Croft and Coombs, 
2003). Although AmBisome has been approved for the treatment of visceral 
leishmaniasis the drug dosage delivered is low compared to dosage required to treat 
visceral leishmaniasis especially in Africa.  
Buparvaquone (BPQ), an approved veterinary drug for theileriosis treatment, 
has shown promising activities against Leishmania spp. ( Croft et al., 1992). Althoug 
BPQ showed anti-leishmanial activity at nanomolar concentrations (Croft et al., 
1992), it has limited in vivo efficacy for VL ( Croft et al., 1992) and CL (Garnier et 
al., 2007) attributed to its poor distribution and low availability.  Besides that BPQ 
has a low water solubility (<1 mg/L) resulting in poor solubility in biological media 
such as gastric fluids (Müller and Jacobs, 2002). Liposomes have been widely used 
3 
 
as safe and effective vehicles for improving drug delivery of drugs with poor 
solubility (Croft et al., 1992) and high toxicity.  As highlighted above, liposomal 
Amphotericin B has been used to treat leishmaniasis with fewer toxic effects ( Bern 
et al., 2006 and Sundar et al., 2011).  
This study, thus aims to prepare formulations of liposome particles to 
encapsulate the drug buparvaquone and to study its release profile. The potential of 
liposome to encapsulate buparvaquone was explored to enhance encapsulation which 
is a common problem with buparvaquone due to its poor solubility. The liposomes 
produced will include two different membrane stabilizers cholesterol and alpha-
tocopherol which can help prevent formation of leaky liposomes.  
 
1.2DRUG DELIVERY  
Generally, the term drug delivery refers to the various methods or systems used to 
ensure drugs are administered effectively into the body (Sivakumar and Rao, 2001, 
Karalis et al., 2010). These systems must take into account a number of needs, 
ranging from ease of delivery to effectiveness of the drugs. The efficacy of a drug 
product depends on the amount of active moiety absorbed from its formulation and 
how rapidly the absorption process takes place. Hence drug delivery systems also 
need to consider the way in which a drug is metabolized by the body. For example, 
some drugs are destroyed in the intestinal tract, which means that they should not be 
introduced to the body through conventional routes which pass through the intestine. 
Others may be dangerous in large amounts, which means that a time release method 
should be used to deliver the drug to avoid toxicity (Dass, 2008).  
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Nanotechnology holds a significant potential as an effective drug delivery 
system (Karalis et al., 2010). Nanocarriers of various geometries and composition 
materials such as nanocapsules, micelles, liposomes, polymeric nanoparticles, solid 
lipid nanoparticles have been developed for the delivery of different therapeutics 
(Zeng et al., 2011). Colloidal drug carriers like emulsions, liposomes and 
nanoparticles have generated great interest to drug delivery mainly due to their 
versatile nature (Date et al., 2007). The discovery of liposomes contributed to a great 
leap in drug delivery research (Date et al., 2007). Liposomes are most extensively 
investigated amongst various colloidal carriers. Knowledge of liposome behavior in 
vitro enabled more rational designs of liposomes for the specific treatment of 
diseases (Sabin et al., 2010). At present, a number of companies work exclusively 
with liposomes for the development of different therapies: antibiotics, antitumor 
drugs, allergic sensitization formulas, gene therapy, and so on (Huang and 
MacDonald, 2004). 
Liposomal drug delivery systems have been extensively studied for its potential 
effectiveness in reducing the toxicity of drugs (Stenekes et al., 2000, Webb et al., 
2007 ). After their discovery by Bangham, liposomes have been developed as non 
toxic, biodegradable and non-immunogenic drug delivery vehicles. Liposomes are 
versatile and unique as they have the capacity to incorporate both 
hydrophobic/lipophilic and hydrophilic drug (Sharma and Sharma, 1996, Huang and 
MacDonald, 2004). 
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1.3 LIPOSOMES AS A DRUG DELIVERY SYSTEM 
1.3.1Liposome: Definition and Classification  
Liposome was accidently found by Alec Bangham while studying blood clotting. He 
found that phospholipids when combined with water immediately formed a sphere. 
This was because phospholipids has two ends in its structure (Sabin et al., 2006). 
One end has the affinity towards water and the other end is water insoluble (Shailesh 
et al., 2009). In the early years of their applications, liposomes were prepared from 
various lipid classes identical to those present in most biological membranes. 
Liposomes are broadly defined as lipid bilayers surrounded in an aqueous 
space. Classification of liposomes can be divided into three classes; multilamellar 
vesicles (MLV) consist of several (up to 14) lipid layers (in an onion-like 
arrangement) separated from one another by a layer of aqueous solution. The 
diameters of these vesicles are over several hundred nanometers. The second one is 
known as small unilamellar vesicles (SUV) which are made out of a single lipid layer 
of 25–50nm in diameter. Large unilamellar vesicles (LUV) are a very heterogeneous 
group of vesicles that are surrounded by a single lipid layer. The diameter of these 
liposomes ranges from 100 nm up to cell size (giant vesicles) (Riaz, 1995, Sharma 
and Sharma, 1996, Chatterjee and Banerjee, 2002). 
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Figure1.1: Schematic representation-types of liposomes (Yang et al., 2011)  
 
 
 
     Figure 1.2: The basic structure of liposome (Pattnaik and Ray, 2009) 
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1.3.2 Mechanisms of Liposome Uptake and Drug Release 
One common strategy for the delivery of encapsulated and/or intercalated material 
via liposomes exploits the pH gradients. The release of liposomes entrapped drug is 
also affected by various mechanisms which include passive diffusion of drug across 
the liposome membrane and perturbation of liposome membrane by intracellular 
and/or extracellular proteins in the tissue. These mechanisms operate simultaneously. 
Liposome uptake is by endocytosis, where liposomes are subjected to acidiﬁcation 
along the endosomal pathway from early endosomes to lysosomes. The extent of 
release can be estimated and controlled by in vitro experiments in simulated 
conditions (Riaz, 1995). Phagocytosis/endocytosis occurs when endosomes take in 
liposomes. They fuse with lysosomes where digestion occurs, breaking open the 
liposomes after which it results in destabilization of the liposome bilayer releasing 
encapsulated material. This mechanism is necessary for mediating lipid 
destabilization, and therefore the release of encapsulated material in liposomes is 
restricted to the lumen of endosomal vesicles and the cytosol (Pollock et al., 2010).  
Endocytosis of liposomes depends on their size. MLVS are endocytosed by 
various cells. Liposomes larger than 0.4µ cannot deliver entrapped material into 
cytoplasm. In general, the larger the liposomes size the faster the clearance. Large 
MLV are cleared mostly by liver cells. Increased clearance is desired when the RES 
is the site of action of the entrapped drug. Negatively charged liposomes are cleared 
faster than neutral or positive liposomes due to the interaction of liposomal 
membrane with plasma component. Intravenous administration of liposome is 
rapidly removed from the circulation by RES. The liver has the highest rate of 
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clearance followed by spleen. The discontinuous capillary walls in the liver allow the 
penetration of liposomes less than 0.2µ (Pattnaik and Ray, 2009). 
1.3.3Phospholipids As Liposomal Matrix 
Phospholipids are the basic building block and the major component of every cell 
membrane in the human body. How they work forming a membrane is elegant and 
miraculous (Memoli et al., 2000). Each phospholipid molecule has three major parts, 
one head and two tails. The head is made from choline, phosphate, and glycerol. The 
head is hydrophilic, it is attracted to water and as for the tails they are made of a 
long, essential fatty acid chain. These fatty acids are hydrophobic so they are repelled 
by water. When phospholipids are placed in an aqueous solution, the hydrophilic 
heads of the phospholipids form a line side by side with their tails behind. Then 
because the tails are hydrophobic, another phospholipid layer will line itself up tail-
to-tail in response to the same aqueous environment. This natural alignment creates 
two-rows of tightly fitted phospholipid molecules, called a phospholipid bilayer. It is 
these phospholipid bilayers that form the membranes around and within every cell in 
our bodies (Yang et al., 2011). 
One bilayer is about one 1,000th the thickness of a sheet of paper. It is these 
liposomal bubbles that are part of every application of liposomal drug delivery 
technology. Since the body is literally held together with phospholipids, these 
liposomal spheres are readily accepted by the body as essential building materials 
and their tiny size enables them to be quickly assimilated into the bloodstream for 
delivery throughout the body (Struppe et al., 2000, Parks et al., 2000). Liposomes 
can be formulated by phospholipids derived naturally or synthetically. One of the 
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most common natural phospholipids is phospatidylcholine (PC). It is an amphipathic 
molecule and is also known as lecithin (Memoli et al., 2000) which are commonly 
derived from egg or soybean.  
 
Figure 1.3: Phospholipid bilayer composed of hydrophobic non-polar tails and   
                hydrophilic polar heads (Belhocine and Prato, 2011) 
                     
1.3.4 Phosphatidylcholine and Liposome 
Phosphatidylcholines (PC) are a class of phospholipids that incorporate choline as 
the head group. They are a major component of biological membranes and can be 
easily obtained from a variety of readily available sources such as egg 
yolk or soy beans from which they are mechanically or chemically extracted. They 
are also a member of the lecithin group commonly found in animal and plant tissues. 
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The name "lecithin" was originally derived from the Greek term lekithos 
which means egg yolk. This name was first given by Theodore Nicolas Gobley, a 
French chemist and pharmacist in 1847, to the egg yolk’s phosphatidylcholine he 
identified. Phosphatidylcholines are such a major component of lecithin that in some 
contexts the terms are synonymous. However, lecithin extract consists of a mixture 
of phosphatidylcholine and other compounds like phosphatidylethanolamine and 
phosphatidylisotinol (Singhvi and Singh, 2011). 
 
 
Figure 1.4: The Structure of Phosphotidylcholine(Lecithin) (Raut et al., 2012) 
1.3.5 Safety and Biocompatibility of Liposomes  
The use of liposomes as a drug carrier system was proposed by Gregoriadis & 
Ryman in the early 70’s (Gregoriadis and Ryman, 1972, Kozubek et al., 2000). Since 
this first report, liposomes were developed as an advanced drug delivery vehicle. 
Liposome is regarded as a safe drug carrier as they are generally considered non-
toxic, biodegradable and non-immunogenic. Incorporation of a drug with liposomes 
markedly changes its pharmacokinetics and lowers its systemic toxicity; furthermore, 
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the drug can be prevented from early degradation after introducing to the target 
organism (Gregoriadis and Davis, 1979). The use of liposomes for the delivery of 
various active compounds is recognized in relation to water solubility of the 
compound. When the compound is water soluble, the size and volume of the aqueous 
compartment of the vesicle is crucial. In contrast, hydrophobic compounds will 
prefer incorporation into the lipid (amphiphile) layer that constructs the vesicle. 
Depending on the need, one can use SUV/LUV type or MLV type vesicles 
for effective entrapment and delivery of the drug to the target tissues or cells. The 
charge properties and interactions of the active compound with vesicle forming 
molecules will determine the efficacy of entrapment, i.e., the amount of the 
compound that can be “loaded” into a single vesicle. On the other hand, the 
composition of the molecules used for the formation of the vesicular structure will 
affect the fate of vesicles from the site of their introduction to the interaction with 
components of the body (e.g., surface charge, serum proteins, lipoproteins, opsonin 
system, and phagocytic system) and finally target cells. To be clinically successful, 
liposomal formulation should be able to encapsulate high amount of drug with proper 
loading stability. Liposomes can be made to contain an antigen, an antibiotic, an 
allergen, a drug substance or a gene (as in gene therapy) (Huang et al., 2006).  
Depending on the requirements of each drug substance; the liposome 
characteristics can be modified. To reduce the rate of liposome degradation and 
therefore to slow down the release of the contents, the composition and size of the 
spheres can be modified. Liposome affinity for a given tissue can also be increased 
by varying vesicle composition, electrical charge or by adding receptors or adhesion 
factors contributing to increase the amount of drug present in the target tissues or 
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organ. An example of this effect is provided by doxorubicin, an expensive toxic 
antitumor drug that is used in human medicine. Doxil is a pegylated (polyethylene 
glycol coated) liposome-encapsulated form of doxorubicin. It was developed to treat 
Kaposi's sarcoma, an AIDS-related cancer that causes lesions to grow under the skin, 
in the lining of the mouth, nose, throat or in other organs. The polyethylene glycol 
coating results in preferential concentration of Doxil in the skin. However, this also 
results in a side effect called palmar plantar erythrodysesthesia (PPE), more 
commonly known as hand-foot syndrome. Following the administration of Doxil, 
small amounts of the drug can leak from capillaries in the palms of the hands and 
soles of the feet. The result of this leakage is redness, tenderness, and peeling of the 
skin that can be uncomfortable and even painful. The prevalence of this side effect 
limits the Doxil dose that can be given as compared with doxorubicin in the same 
treatment regimen, thereby limiting potential substitution. Substitution would be 
desirable because liposome-encapsulated doxorubicin is less cardiotoxic than 
unencapsulated doxorubicin. Doxil is also approved by the FDA for treatment of 
ovarian cancer and multiple myeloma (Basu, 2005).  
1.3.6 Fabrication Techniques for the Production of Liposomes 
There are various  modes for liposome fabrication and a wide variety of conventional 
techniques that can be used to produce liposomal formulations, including Bangham, 
detergent depletion, ether/ethanol injection and emulsion methods (Mozafari, 2005). 
All methods for producing liposomes require lipids to be combined with an aqueous 
phase. The conventional methods generally involves a lipid solution being produced 
using an organic solvent prior to dispersion into the aqueous phase. However, the use 
of a volatile organic solvent may affect the chemical structure of an entrapped 
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chemical and also contribute to the toxicity and stability of the liposomes (Patel et 
al., 2011). 
1.3.6(a) Bangham Method 
Bangham method, also known as the hand shaken or thin film hydration method is 
one of the most traditionally used techniques for the fabrication of liposomes. The 
process is carried out by dissolving lipids in an organic phase, followed by the 
removal of the organic solvent, usually via evaporation. This results in the formation 
of a thin lipid film (crude liposome). The final step is the hydration of the lipid film 
with an aqueous media, carried by agitation to detach the swelling lamellae from the 
vessel surface. Then it forms a sealed spherical structure (liposomes). The solvent 
removal stage is time-consuming since it often requires several hours of exposure to 
high vacuum. 
Liposomes produced via Bangham method are often several microns in size. 
Although Bangham method is one of the simplest methods for liposome formation, it 
has limited use due to low entrapment efficiency, difficulty in removing organic 
solvent, homogenization and is only suitable for small scale production (Mohammed 
et al., 2004, Mozafari, 2005). One alternative as shown in a previous study by Ran 
and Yalkowsky (Ran and Yalkowsky, 2001) was to produce liposomes using the thin 
film method by replacing the common organic solvent chloroform with halothane, a 
non-flammable, non-carcinogenic inhalation anesthetic (Jain et al., 2003, Santos et 
al., 2004). 
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1.3.6(b) Ethanol Injection Method 
Ethanol injection method is one of the easiest and fastest method to produce 
liposomes. The method of preparation is carried out by injecting a small volume of 
ethanol containing lipid solution into a large volume of water or any other aqueous 
phase using a fine needle. The force by injections ensures homogeneous mixing of 
the lipids. The solution is then subjected to ethanol evaporation to eliminate the 
organic solvent to give a coarse liposomal solution. Later, liposomes are sonicated 
and homogenized for further downsizing (Pons et al., 1993). 
1.3.6(c) Detergent Depletion Method 
The detergent depletion method is a mild process for producing a wide variety of 
vesicle types and highly homogeneous liposomes. The method is based on the 
formation of detergent-lipid micelles, followed by the removal of the detergent to 
form liposomes. Detergent-lipid micelles can be formed by either hydrating a lipid 
with a detergent solution or by drying both lipid and detergent from an organic 
solution then adding an aqueous solution. The detergent associates with the lipid, 
protecting the hydrophobic sections from interacting with the aqueous phase, and 
thus micelles are formed rather than vesicles. Afterward, the detergent is removed 
from the micelle solution, using dilution by 10 to 100 fold, dialysis, column 
chromatography or adsorption, to form the vesicles (Betageri, 1993). 
Despite dilution being the simplest method for detergent removal, the 
disadvantage is that the final concentration of liposomes in the solution is low and 
entrapment of any hydrophobic compounds is poor. The detergent might also 
remains in the formulation and should be removed via other methods. The size and 
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homogeneity of liposomes produced using detergent depletion are based on the rate 
at which the detergent is removed and the initial ratio of detergent to phospholipids. 
The method is very time consuming and equilibration of the micelles can be a slow 
process. Another potential disadvantage of the process is that the methods used to 
remove the detergent may also remove any other small hydrophilic compounds 
(Betageri, 1993). 
1.3.6(d) Emulsion Method 
The production of liposomes using emulsion method generally involves the 
formation of a water-in-oil emulsion through the addition of a small amount of 
aqueous media to a larger volume of immiscible organic solution containing the 
phospholipids. The mixture is agitated to disperse the aqueous media as tiny droplets 
throughout the organic solvent and the lipid aligns itself into a monolayer at the 
boundary between the organic and aqueous phases. The size of the droplets can be 
controlled by the agitation applied and the amount of lipid present. There must be 
sufficient lipid to surround the droplet or it may fuse with other droplets. The water-
in-oil emulsion is transformed into a liposomal suspension through the formation of a 
double emulsion. The organic solution containing the water droplets is added to a 
large volume of aqueous media and agitated, producing a water-in-oil-in-water 
emulsion. A lipid monolayer also forms around the organic droplets producing 
aqueous cores surrounded by two lipid monolayers that are separated by an organic 
layer (Betageri, 1993). Unilamellar liposomes with high entrapment of the initial 
aqueous media can then be formed by the removal of the organic solvent, for 
example, by passing a stream of nitrogen through the double emulsion. The lipid, 
solvent composition and shaking time period were controlled so that multiple water 
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droplets become contained within a single organic droplet in the double emulsion. 
Once the organic solvent was removed, the droplets formed multiple compartments 
within a single lipid vesicle, usually 1–2 μm in diameter. Multivesicular liposomes 
provide the potential to deliver multiple compounds that are unstable when combined 
(Mozafari, 2005). 
1.3.7 Excipients used in Formulating Liposomes 
1.3.7(a)   Cholesterol 
Cholesterol is one of the major components found in membranes and is also an 
additive used widely in formulating liposomes (Sideratou et al., 2000). Their role 
includes membrane organization, dynamics and function (Kepczynski et al., 2008). 
Insufficient quantity, cholesterol aids in liposomes stability (Sivakumar and Rao, 
2001). Cholesterol also increases packing density of the phospholipids molecules and 
reduced the bilayer permeability to ions and solutes (Semple et al., 1996). The 
presence of cholesterol exerts a profound influence on the properties of the lipid 
bilayers of the liposomes. It has been known for several decades that the addition of 
cholesterol to a fluid phase bilayer (mainly unsaturated lipids) decreases its 
permeability to water (Sivakumar and Rao, 2001). A liposome that is made from 
100% unsaturated lipid in fluid phase cannot hold its encapsulated content and the 
encapsulated water soluble drugs will leak out over time. Therefore, the addition of 
cholesterol is necessary in order to prevent the leakage of the encapsulated drug from 
the liposomes.  
Cholesterol prevents the leakage of drug as the molecules fill in the free space 
that was formed due to the kink in the chain of the unsaturated lipids and this 
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decreased the flexibility of the surrounding lipid chains. This interaction also 
increases the mechanical rigidity of the fluid bilayers and decreases their lateral 
diffusion. In contrast, the addition of cholesterol to gel phase bilayers (mainly 
saturated lipids) disrupts local packing orders and increases the diffusion coefficient 
and decreases the elasticity of the vesicle. Liposomes made from 100% saturated 
lipids are leak-proof in the absence of the cholesterol. One of the main reasons for 
addition of cholesterol to liposomes that are made from saturated lipids is to increase 
the phase transition temperature. The phase transition temperature (Tm) of the 
mixture of the lipids in the liposomes will be increased, but not eliminated, by the 
addition of cholesterol. Cholesterol increases the Tm indicating that the incorporation 
of cholesterol increases the thermal energy and changing its state from the solid-gel 
to the liquid crystalline phase. This enables the retention of more drugs due to its 
colloidal stability (Drummond et al., 2008) and increased circulatory lifetimes of 
liposomes (Kirby et al., 1980).  
Furthermore, it has been suggested that the cholesterol increases the half-lives 
of circulating liposomes as a result of a dual functionality of membrane cholesterol 
(Patel et al., 2011). First, as mentioned previously, cholesterol decreases membrane 
permeability and affords the bilayer a greater resistance to destabilization by blood 
components. Second, it has been demonstrated that cholesterol-rich liposomes 
possess a lower affinity for uptake by hepatic Kupffer cells, suggesting that 
cholesterol inhibits the binding of serum opsonins to liposomes (Semple et al., 1996). 
 
18 
 
 
Figure 1.5: The Structure of Cholesterol (Ahmad, 1994) 
1.3.7(b)  -Tocopherol 
-tocopherol, the major component of Vitamin E, is a lipid-soluble hydrocarbon 
compound that partitions into lipid storage organelles and cell membranes. It is an 
efficient scavenger of lipid peroxyl radicals and, hence, it is able to break peroxyl 
chain propagation reactions in cellular membranes preventing lipid peroxidation. 
Considerable evidence suggests that liposome-encapsulated antioxidants can be 
superior to the corresponding free antioxidants in this regard (Xiong et al., 2009). -
tocopherol is able to reduce the negative effects of high phospholipid concentrations 
and perhaps permit the use of liposome concentrations that would otherwise be toxic 
(CR et al., 1998). In a study with model membrane systems, α-tocopherol was shown 
to be intercalated into phospholipid bilayers with the long axis of the molecule 
oriented parallel to the lipid hydrocarbon chains, and it was able to rotate about its 
long axis and diffused laterally within fluid lipid bilayers. Because of its membrane 
stabilizing effect, α-tocopherol has been used in the preparation of liposomes for the 
delivery of several drugs (Suntres and Shek, 1994). 
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The maximum amount of α-tocopherol that can be contained in egg 
phosphatidylcholine or phosphatidylcholine liposomes is approximately 33%. -
tocopherol alters the membrane characteristics of liposomes by making them more 
stable and less permeable to aqueous solutes and highly resistant to protein-induced 
disruption. The suppression of protein-induced disruption is more pronounced 
with α-tocopherol than with cholesterol even at lower molar ratios. In addition, α-
tocopherol in liposomes can undergo spontaneous intermembrane transfer to an 
acceptor membrane without the fusion of the protein with α-tocopherol liposomes. 
Thus, liposomes containing α-tocopherol (15 to 30 mol %) may be useful for 
delivering physiological quantities of this vitamin component or other drugs to cells 
in culture or to tissues in vivo (Sarkar et al., 2002). 
 
 
 
Figure 1.6: The Structure of -tocopherol  (Reto et al., 2003) 
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1.3.8 Advantages of Liposomes Application in Drug Delivery 
One of the most important characteristics of liposomes is that they are avidly 
phagocytosed by macrophages and other cells of the reticuloendothelial system upon 
intravenous injection (Bru et al., 2002). As a result, they make excellent delivery 
system for many purified antigens. Some of the other properties of liposomes, 
notably entrapment and retention of virtually any pharmacologically active agent, 
structural versatility and an apparently innocuous nature, were attributes of a 
potentially powerful tool for the control of drug action (Huang and MacDonald, 
2004).  
There are many other reasons to use liposomes as drug carriers. The first is the 
solubilisation. Liposomes may solubilise lipophilic drugs that would otherwise be 
difficult to administer intravenously. Second is protection; liposome encapsulated 
drugs are inaccessible to metabolizing enzymes; conversely, body components (such 
as erythrocytes or tissues at the injection site) are not directly exposed to the full dose 
of the drug. Third is prolonged duration of action; liposomes can prolong drug action 
by slowly releasing the drug in the body. Fourth is the directing potential whereby 
targeting options change the distribution of the drug through the body. The fifth 
reason is internalization. Liposomes are endocytosed or phagocytosed by cells, 
where liposome dependent drugs as the case of leishmaniasis can be up taken by 
cells (Proulx et al., 2001) The sixth reason is amplification where liposomes can be 
used as adjuvant in vaccine formulation. The drawbacks of buparvaquone in treating 
leishmaniasis due to its solubility and hydrophobic nature make liposome a logical 
drug carrier of buparvaquone. Hence the formulation study of buparvaquone was 
carried out. 
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1.4 Leishmaniasis 
Neglected Tropical Diseases (NTDS) caused by bacterial, protozoan and helminthes 
which are responsible for approximately 534,000 deaths yearly include 
leishmaniasis, African trypanosomiasis, dengue fever, malaria, schistosomiasis, 
tuberculosis, chagas disease, leprosy, lymphatic filariasis and onchocerciasis (Nwaka 
and Hudson, 2006). These are endemic diseases in tropical and sub tropical regions 
(Croft and Yardley, 2002). These tropical infections were used to be found 
throughout the more temperate climates of North America and Europe. These 
diseases were eradicated from North America and Europe as a result of good 
sanitation, hygiene, and vector-control methods, as well as a rise in the standards of 
living. Economic factor rather than climate contributes to the occurrence of these 
infections now considered "tropical" and is found mainly in poorer, developing 
countries. Countries like Iran and Afghanistan exhibit high rates of tropical disease 
even without tropical climate (Sharma and Singh, 2008). 
 
Leishmaniasis is a parasitic disease caused by infection of 20 different 
Leishmania parasites. The disease is transmitted between mammalian host by the bite 
of Phlebotomus sand flies infected by the parasites (Sharma and Singh, 2008). 
Leishmaniasis takes several forms of occurrence and the most common forms is 
cutaneous leishmaniasis that holds responsible for skin sores. Whilst visceral 
leishmaniasis the more fatal form of the parasite infects the internal organs of the 
body (for example, spleen, liver, and bone marrow) (Croft et al., 2006). 
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1.4.1 Signs and Symptoms of Leishmaniasis 
People infected by cutaneous leishmaniasis would commonly have one or more sores 
on their skin that over time changes in its size and appearance. The sores may end up 
as an ulcer with appearance similar of a volcano (a raised edge and central crater). 
Some people would develop sores that are covered by a scab. The degree of pain 
differs from case to case.  
As for visceral leishmaniasis the symptoms would include fever, weight loss, 
and an enlarged spleen and liver. It also causes abnormal blood counts. For example, 
patients would usually have low blood counts for red blood cell count (condition 
known as anemia) or low white blood cell count, and low platelet count. Symptoms 
of leishmaniasis do not presume in all cases. However, after the sand fly bite, the 
skin sore of cutaneous leishmaniasis usually develops within a few weeks or months. 
For cases of visceral leishmaniasis patients usually become sick within months or 
even as long as years after being bitten by the leishmaniasis vector (Croft and 
Yardley, 2002) 
 
1.4.2 Distribution of Disease 
Each year 1.5 million cases of cutaneous leishmaniasis and 500,000 new cases for 
visceral leishmaniasis are recorded (Croft et al., 2006, Venkatesh et al., 2009 ). 
Leishmaniasis is found in focal areas of about 88 countries on the world map. Some 
of these countries have records for the world’s highest occurring cases of 
leishmaniasis: 
a) More than 90% of reported cases for cutaneous leishmaniasis occur in   
Afghanistan, Algeria, Iran, Iraq, Saudi Arabia (also known as Old World) and 
for the New World, it includes Brazil and Peru. N.Africa, South Asia, Middle 
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East, Tunisia Ethiopia, India, Sudan, Bangladesh, China, Central and West 
Asia, Central and South America, Kenya, Mexico, Belize, Guatemala and 
Ecuador (Refer to Figure 1.7 a). 
b) Over 90% of cases recorded for visceral leishmaniasis (Organization, 2014)   
were in countries including India, Bangladesh, Nepal, Sudan and Brazil have 
Venezuela, Brazil, Peru, French, Guiana, Guyana, Surinam, Panama and 
Costa Rica (Refer to Figure1.7 b). 
 
1.4.3 Epidemiology 
Humans are mainly infected by several Leishmania species that include Leishmania 
donovani, which causes visceral leishmaniasis also known as kala azar; Leishmania 
tropica and Leishmania brasiliensis which cause cutaneous leishmaniasis. Although 
it has occurrence worldwide, the predominant occurrence of visceral leishmaniasis is 
encountered in India, South America, Central Asia, the Middle East, and Africa. As 
for cutaneous leishmaniasis caused by L tropica, the most common encounters are 
along the shores of the Mediterranean, throughout the Middle East, central Africa, 
and parts of India (Croft et al., 2006). The form of cutaneous leishmaniasis by L 
brasiliensis is more confined to Central America and South America (Croft et al., 
1991, Sharma and Singh, 2008).  
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     (a) 
                   
 
                 (b) 
Figure 1.7 Distribution of (a) cutaneous leishmaniasis and (b) visceral leishmaniasis   
in the world (World Health Organization, 2014) 
 
          
Primarily a zoonotic disease, leishmaniasis can be caused by 20 species of protozoa 
pathogenic for humans belonging to the genus Leishmania (Quellette et al., 2004). 
